Email Facebook Twitter

Tech company Mporium delivers an outstanding set of Q1 results says CEO De Groot
IronRidge Resources CEO hails spectacular lithium project and money making potential for gold

Member Info for Hugh-Jarse

Send a private message to Hugh-Jarse

Member Since: Fri, 15th Nov 2013

Number of Share Chat Posts (all time): 495
Number of Share Chat Posts (last 30 days): 12

Last Posted: Tue 07:17

Post Distribution over the last 30 days

9 Apr '19

..and needed that bounce too ... up another +3.01% today.

Hopefully, the trigger is 'fresh' ISA money coming in,
long may it continue.

Follow the money :-)
5 Apr '19

Greetings one and all.
Been following KAPE since Feb 2017 via 'ST' with the idea of
one day jumping in when the cycle presented the opportunity.

Anyone, throw up some reasons why this is at a 15 month low?
Yes the Results on 19Mar 2019 omitted the dividend. And we
now have a prolonged extension looming in regards to the 'B' word.
Acquisitions have continued unabated.

I prefer KAPE ("..the poor mans Sophos..") to SOPH itself, did wonder
though if any here are holding both. C'mon your secret's safe with me :-)
2 Apr '19

For anyone new researching. From the ARS site:

...and thank you Trump for giving the entry points !
28 Mar '19

--> mushroomkid:

It all goes back to the Interim release on 06Feb when they announced/declared.

"In line with our policy of a 33% full year dividend payout ratio, the Board has declared an interim dividend of 10p per share (2018: 9p). The interim dividend will be paid on 9 April 2019 to holders of ordinary shares on the register at the close of business on 8 March 2019."
"As a result of our continuing strong earnings and cash performance, we are proposing a 30p per share cash return to shareholders through a B Share Scheme, which will be in addition to the interim dividend. This Scheme enables all shareholders to participate equally in proportion to their holdings and should be treated as capital for most UK tax resident shareholders. Assuming it is approved by shareholders payment is expected to be made in April 2019. The Scheme will be accompanied by a share consolidation to maintain share price comparability."
27 Mar '19

Return of Capital and Consolidation:

".....will pay at a rate of 30p per share held,
then consolidated on the basis of x20 new shares for every x21 held"
18 Mar '19

" Motif Bio seeks to advance iclaprim towards approval. We have submitted a meeting request and package to the FDA and expect to work collaboratively with the Agency over the coming weeks."
15 Mar '19

believe a bearcast mentioning MTFB is up.
Anyone post the gist of what is said.

Except for images of that damn 'Greek Hovel'
I don't have access.
15 Mar '19

--> n4apenny:

all depends, a placing @5p or placing @20p...
all depends on the actual outcome of the meeting
or the anticipation of the outcome. Defies all logic.
15 Mar '19

What if the radio silence in regards to the meeting is because
a raise event is planned before the meeting with FDA.

Just surmising...which will come first, may not necessarily follow logic.
14 Mar '19

Not a bad day. Considering the WA fiasco in Parliament,
and Theresa's croaky
Into the mixture came the Spring Budget/Statement too.
OPTI is the calm in all this distraction.
Feels good to be in this share.
13 Mar '19

From SBTX site:

31Jan 2019: "The final 60 volunteers are now being treated and the Company remains on track to complete the study

during Q1 2019 as expected."

Anyone, feel free to update the above.... cheers Hugh.

Sign up for Live Prices
Top Recommended
Hot Chat Topics
Top recommended posters in the last 30 days

Member Login

Forgotten your password?


Don't have an account? Click here to Register Free!

Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.